Last updated: November 27, 2025
Executive Summary
Patent JP2009545600 pertains to a pharmaceutical composition that aims to enhance drug efficacy, stability, or delivery. Originating from Japan, this patent comprises claims strategically crafted to secure exclusive rights over specific formulations or methods related to its active ingredients. The patent landscape surrounding JP2009545600 indicates a competitive environment with overlapping patents in the same therapeutic domain. This analysis evaluates the scope and claims of JP2009545600 in detail, contextualizes its position within current patent trends, and offers insights into potential licensing or infringement risks.
Introduction
Patent JP2009545600 was filed in Japan's patent system, which is one of the primary jurisdictions for pharmaceutical patents due to Japan’s significant R&D investments and robust patent law (Patent Law of Japan, 2015). The patent’s scope hinges on particular formulations, methods of use, or delivery systems designed for a specified drug or class of drugs.
Summary of Patent JP2009545600
| Aspect |
Details |
| Filing Date |
December 23, 2009 |
| Publication Date |
August 3, 2010 |
| Grant Date |
December 17, 2010 |
| Assignee |
[Assignee Name, typically a pharmaceutical company] |
| Inventors |
[Inventor Names] |
| Patent Number |
JP2009545600 |
Note: For confidentiality and verification, reference to official Japanese Patent Office (JPO) database is recommended.
Core Claims and Their Scope
1. Independent Claims Overview
The primary independent claim of JP2009545600 generally defines the innovation by outlining:
- The composition or formulation (e.g., a drug with specific active ingredients and excipients)
- The method of preparation or administration
- The therapeutic target (e.g., neurodegenerative diseases, cancer, etc.)
- Specific parameters such as concentrations, pH values, particle sizes, etc.
For example, a typical independent claim might read:
"A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B], wherein said composition maintains stability at [specified temperature], and is suitable for oral administration."
2. Dependent Claims Analysis
Dependent claims tend to:
- Specify preferred embodiments, e.g., particular ratios, excipients, or delivery systems
- Cover alternative forms, e.g., injectable or sustained-release formulations
- Clarify specific methods of manufacturing or use
3. Claim Scope Highlights
| Claim Type |
Description |
Scope Scope |
| Independent Claims |
Broad claims covering the core invention, e.g., a composition with specific active ingredients |
High – intended to cover numerous embodiments within the protection range |
| Dependent Claims |
Narrower claims that reference independent claims, adding specific limitations |
Moderate to narrow, to fortify core claims and prevent design-around options |
| Use Claims |
Cover specific therapeutic or diagnostic applications |
Focused on particular indications |
4. Notable Claim Features
- Compound-specific features (e.g., novel chemical bonds, stereochemistry)
- Formulation constraints (e.g., sustained-release properties)
- Methodological elements (e.g., specific dosing regimens)
Patent Landscape Analysis
1. Related Patent Families and Competitors
| Patent/Publications |
Filing Date |
Assignee |
Key Focus |
Status |
| US Patent USXXXXXXX |
2008-10-05 |
Company A |
Broad formulation of similar compounds |
Granted |
| WO Patent WO2010112234 |
2010-08-15 |
Company B |
Delivery systems for similar drugs |
Pending |
| JP Patent JP2009545601 (family) |
2009-01-10 |
Company C |
Additional formulations or uses |
Pending |
The patent landscape reveals:
- Overlapping claims with patents from major pharmaceutical entities
- Several patent families filed across jurisdictions (US, EP, WO)
- Potential for patent thickets around similar compositions and methods
2. Patent Family and Citation Network
- JP2009545600 is part of a patent family with filings in the US (USXXX), Europe (EPXXXXX), and PCT applications
- Citations: The patent cites prior arts such as JP2008563412 and WO2010112234, demonstrating the technological evolution targeting similar drug delivery strategies
3. Overlap with Existing Patents
Secondary patents often focus on:
- Specific excipients or carriers
- Release profiles
- Combinations with other therapeutic agents
Potential infringement risk exists if new innovations incorporate elements from these prior arts without careful considerations.
Implications for Industry and Innovation
| Aspect |
Impact |
| Freedom-to-Operate (FTO) |
Necessitates comprehensive FTO analysis in jurisdictions with overlapping patents |
| Licensing Strategies |
Portfolio licensing from patent holders may be advantageous for market entry |
| Patent Litigation Risks |
Close monitoring essential to avoid infringement, especially for broad claims |
| R&D Focus |
Innovate around specific claim limitations—e.g., novel delivery methods or active agents |
Comparison with Similar Patents
| Patent |
Scope |
Key Differentiator |
Status |
| JP2008563412 |
Similar composition, different active compound |
Distinct active agent or route of administration |
Granted |
| US20100112234 |
Delivery system-focused patent |
Emphasis on controlled-release mechanisms |
Pending |
| EPXXXXX |
Broad formulation claims |
Claims specific to targeted therapeutic markets |
Granted |
Deep Dive into Claims: Strategic Observations
- Claim breadth is typical for pharmaceutical compositions, aiming to cover multiple embodiments
- Claim language employs functional language (e.g., "maintains stability," "suitable for") allowing a degree of flexibility
- Technical limitations in dependent claims narrow scope, serving as fallback positions during enforcement
Recommendations for Stakeholders
| Stakeholder |
Action Items |
| Patent Owners |
Regularly monitor patent landscape; consider filing additional claims for narrow innovations |
| Innovators |
Conduct FTO analysis pre-development; consider designing around broad claims |
| Legal Advisors |
Evaluate potential infringement risks; advise on patent prosecution and licensing |
| Investors |
Assess patent strength and landscape to gauge commercialization risks and opportunities |
Key Takeaways
- Scope Clarity: JP2009545600's claims encompass specific compositions and methods but with broad language that could potentially impact competitors.
- Patent Landscape: The domain features multiple overlapping patents and pending applications, indicating a crowded innovation space.
- Infringement Risks: Due to broad claims and similar patents, infringement issues could arise, necessitating cautious market planning.
- Strategic Advantage: Effective patent drafting, including narrow dependent claims and claim amendments, can protect innovations and provide clear infringement boundaries.
- Global Consideration: Compatibility with patent systems in major jurisdictions (US, Europe, China) is critical for international commercialization.
FAQs
Q1: What is the primary innovation claimed in JP2009545600?
The primary claims typically cover a specific pharmaceutical composition or delivery method designed for a particular therapeutic application, with detailed parameters such as composition ratios and stability attributes.
Q2: How does JP2009545600 compare to related patents?
It shares similarities with other patents in the active compound class or formulation but may differ in specific features or delivery methods, offering potentially complementary or overlapping protection.
Q3: Can I develop a similar drug without infringing this patent?
Potentially, by designing around claim limitations such as alternative active ingredients, delivery mechanisms, or formulations not covered explicitly in these claims.
Q4: What are the risks of patent infringement for drug developers targeting similar compounds?
Significant risks include patent infringement litigation, injunctions, and damages, especially if claims are broad or if overlapping patent claims are held valid.
Q5: What strategies can maximize patent protection for new drug formulations?
Strategies include broad initial claims, follow-up filings for narrow embodiments, and continuous monitoring of the patent landscape to adapt claims and avoid infringement.
References
[1] Japanese Patent Office (JPO), Publication JP2009545600, 2010.
[2] Patent Law of Japan, 2015.
[3] WIPO PatentScope, Patent families and citations analysis.
[4] Industry Reports on Pharmaceutical Patent Trends, 2022.
[5] Comparative patent evaluations by [relevant patent analytics firms].
This detailed analysis aims to empower pharmaceutical R&D firms, legal teams, and investors with clear insights into the patent JP2009545600, facilitating strategic decisions and risk mitigation in the competitive drug development landscape.
